Clinical Trial

Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC

Name: Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC — clinical trial record (NCT07050043)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: LEDANG

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

This is a multicenter, two-arm randomized, parallel group design trial to evaluate superiority and safety of low dose Nivolumab (40mg) combined with standard chemotherapy versus standard chemotherapy alone in patients with non-small cell lung cancer.

Trial Details

NCT Number	NCT07050043
Lead Sponsor	Dr Arvindran A/L Alaga
Conditions	NSCLC (Non-small Cell Lung Carcinoma), First Line Therapy, Locally Advanced/Metastatic NSCLC
Enrollment	123 participants
Start Date	2025-05-19
Primary Completion	2030-12-31 (estimated)
Study Completion	2030-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-07-03